ISRG · Earnings call · 2026Q3T · Full report
Revenue Performance and Mix
INTUITIVE SURGICAL INC · 2026-10-20 · Importance 59 · Surprise 48 · Contradicted
Q3 2026 revenue grew 22% to just over $3 billion, with 84% from recurring revenue. Revenue growth exceeded the 15% increase in da Vinci and Ion procedures, reflecting system-placement growth and a richer mix of da Vinci 5, SP and Ion. Net da Vinci placements that expanded the installed base grew 40%.
Key facts
- Q3 2026 systems revenue grew 30% to $769 million.
- Q3 2026 revenue grew 22% to just over $3 billion, of which 84% was recurring revenue.
- Q3 2026 service revenue increased 22% to $482 million.
- Q3 2026 total I&A revenue grew 18% to $1.8 billion.
- Integrated insufflation was used about 85% of the time on da Vinci 5 and added about $100 per procedure for tube sets connecting to the insufflator.
- Q3 2026 da Vinci I&A revenue per procedure was approximately $1,860, compared with $1,800 a year earlier.
- The Q3 2026 average selling price for purchased da Vinci systems was approximately $1.6 million, flat year over year.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +18.0% | Q3 2026 revenue grew 22% to just over $3 billion, of which 84% was recurring revenue. |
| revenue | positive | realized | +9.5% | Q3 2026 total I&A revenue grew 18% to $1.8 billion. |
| revenue | positive | realized | +6.1% | Q3 2026 systems revenue grew 30% to $769 million. |
| revenue | positive | realized | +3.0% | Q3 2026 service revenue increased 22% to $482 million. |